Research Article|Articles in Press, 103655

Does ferritin level affect the outcomes of autologous stem cell transplantation equally in all diseases?

Published:February 16, 2023DOI:



      In this retrospective study, we evaluated the effect of ferritin levels on the outcomes of autologous stem cell transplantation in patients with MM or lymphoma.


      In this study, 170 patients with measured ferritin levels within one month before transplantation who underwent ASCT with the diagnosis of MM or lymphoma were evaluated. The cut-off value of ferritin was determined as 500 ng/mL to evaluate the transplant outcomes in both groups. The hematological recovery status/duration, febrile neutropenia rate, hospitalization time, transplant-related mortality (TRM) in the first 100 days, and OS were evaluated according to the ferritin level


      Of all patients, 105 (61,8%) were diagnosed with MM and 65 (38.2%) with lymphoma. Ferritin levels had no statistically significant effect on the engraftment status/times, the febrile neutropenia rates, and hospitalization times of both lymphoma and myeloma patients (p > .05). Ferritin level was not significantly associated with TRM in MM (p = .224). However, in lymphoma, ferritin level was significantly associated with TRM (33.3% for ferritin level ≥500 ng/L vs. 5.3% for ferritin level ng/mL, p = .005). There was no statistically significant correlation between ferritin value and OS in MM group [ferritin level ≥ 500 ng/L: 39.9 months (95% CI: 33.7–46.1) and ferritin level 500 ng/mL: 39.4 months (95% CI: 36.5–42.2), p = .446]. Ferritin level was significantly associated with OS in patients with lymphoma [ferritin level ≥ 500 ng/L: 22.1 months 95% CI: 14.7–29.5), ferritin level 500 ng/mL: 27.3 months (95% CI: 22.4–32.2), p = .038]


      High ferritin level is important prognostic factor on survival after ASCT in patients with lymphoma.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ricciuti G.
        • Falcone A.
        • Cascavilla N.
        • Martinelli G.
        • Cerchione C.
        Autologous stem cell transplantation in multiple myeloma.
        Panminerva Med. 2020; 62: 220-224
        • Zahid U.
        • Akbar F.
        • Amaraneni A.
        • Husnain M.
        • Chan O.
        • Riaz I.B.
        • et al.
        A review of autologous stem cell transplantation in lymphoma.
        Curr Hematol Malig Rep. 2017; 12 (217-26)
        • Kaddu-Mulindwa D.
        • Gödel P.
        • Kutsch N.
        • Heger J.M.
        • Scheid C.
        • Borchmann P.
        • et al.
        Salvage high-dose melphalan with autologous stem cell transplantation as bridge to consolidation therapy for chemoresistant aggressive B-cell lymphoma.
        Clin Lymphoma, Myeloma Leuk. 2022; 22: e498-e506
        • Knovich M.A.
        • Storey J.A.
        • Coffman L.G.
        • Torti S.V.
        • Torti F.M.
        Ferritin for the clinician.
        Blood Rev. 2009; 23: 95-104
        • Kikuchi S.
        • Kobune M.
        • Iyama S.
        • Sato T.
        • Murase K.
        • Kawano Y.
        • et al.
        Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome.
        Int J Hematol. 2012; 95: 527-534
        • Kell D.B.
        • Pretorius E.
        Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells.
        Met: Integr biometal Sci. 2014; 6: 748-773
        • Castiella A.
        • Alústiza J.M.
        • Emparanza J.I.
        • Zapata E.M.
        • Costero B.
        • Díez M.I.
        Liver iron concentration quantification by MRI: are recommended protocols accurate enough for clinical practice?.
        Eur Radiol. 2011; 21: 137-141
        • Kanda J.
        • Kawabata H.
        • Chao N.J.
        Iron overload and allogeneic hematopoietic stem-cell transplantation.
        Expert Rev Hematol. 2011; 4: 71-80
        • Olivé A.
        • Juncà J.
        Elevated serum ferritin levels: associated diseases and clinical significance.
        Am J Med. 1996; 101 (author reply 2): 120
        • Armand P.
        • Kim H.T.
        • Cutler C.S.
        • Ho V.T.
        • Koreth J.
        • Alyea E.P.
        • et al.
        Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.
        Blood. 2007; 109: 4586-4588
        • Pullarkat V.
        • Blanchard S.
        • Tegtmeier B.
        • Dagis A.
        • Patane K.
        • Ito J.
        • et al.
        Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation.
        Bone Marrow Transplant. 2008; 42: 799-805
        • Morado M.
        • Ojeda E.
        • Garcia-Bustos J.
        • Aguado M.J.
        • Arrieta R.
        • Quevedo E.
        • et al.
        BMT: serum ferritin as risk factor for veno-occlusive disease of the liver. prospective cohort study.
        Hematology. 2000; 4 (505-12)
        • Kamble R.T.
        • Selby G.B.
        • Mims M.
        • Kharfan-Dabaja M.A.
        • Ozer H.
        • George J.N.
        Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
        Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl. 2006; 12: 506-510
        • Miceli M.H.
        • Dong L.
        • Grazziutti M.L.
        • Fassas A.
        • Thertulien R.
        • Van Rhee F.
        • et al.
        Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients.
        Bone Marrow Transplant. 2006; 37: 857-864
        • Sucak G.T.
        • Yegin Z.A.
        • Ozkurt Z.N.
        • Aki S.Z.
        • Yağci M.
        Iron overload: predictor of adverse outcome in hematopoietic stem cell transplantation.
        Transplant Proc. 2010; 42: 1841-1848
        • Majhail N.S.
        • DeFor T.E.
        • Lazarus H.M.
        • Burns L.J.
        Iron-overload after autologous hematopoietic cell transplantation.
        Leuk Res. 2009; 33: 578-579
        • Greipp P.R.
        • San Miguel J.
        • Durie B.G.
        • Crowley J.J.
        • Barlogie B.
        • Bladé J.
        • et al.
        International staging system for multiple myeloma.
        J Clin Oncol: J Am Soc Clin Oncol. 2005; 23: 3412-3420
        • Giralt S.
        • Stadtmauer E.A.
        • Harousseau J.L.
        • Palumbo A.
        • Bensinger W.
        • Comenzo R.L.
        • et al.
        International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
        Leukemia. 2009; 23: 1904-1912
        • Strasser-Weippl K.
        • Ludwig H.
        Ferritin as prognostic marker in multiple myeloma patients undergoing autologous transplantation.
        Leuk Lymphoma. 2014; 55: 2520-2524
        • Sivgin S.
        • Karamustafaoglu M.F.
        • Yildizhan E.
        • Zararsiz G.
        • Kaynar L.
        • Eser B.
        • et al.
        The prognostic significance of elevated serum ferritin levels prior to transplantation in patients with lymphoma who underwent autologous hematopoietic stem cell transplantation (autoHSCT): role of iron overload.
        Clin Lymphoma, Myeloma Leuk. 2016; 16 (Suppl): S152-S158
        • Mahindra A.
        • Bolwell B.
        • Sobecks R.
        • Rybicki L.
        • Pohlman B.
        • Dean R.
        • et al.
        Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma.
        Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl. 2008; 14: 1239-1244